Novartis Ag

Alexander Baxter Smith

Nicolas Soldermann

Romain Wolf

Pascal Furet

Frederic Zecri

Nigel Graham Cooke

Frank Stowasser

Anette Von Matt

Ian Lewis

Gregory John Hollingworth

Christina Hebach

Paulo Antonio Fernandes Gomes Dos Santos

Giorgio Caravatti

Konstanze Hurth

Gebhard Thoma

Maurice Van Eis

Sylvie Chamoin

Henrik Moebitz

Nicola Tufilli

Karen Kammertoens

Ross Strang

Klemens Hogenauer

Nadege Graveleau

Klemens Hoegenauer

Frédéric Zecri

Peter Buehlmayer

Klemens Högenauer

Nicola Tuffilli

Frédèric Zecri

Ross Sinclair Strang

Christoph Kalis

The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

Use of inhibitors of the activity or function of PI3K

The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R, R, Rand Rare as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R, Rand m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

Tetrahydro-pyrido-pyrimidine derivatives

The present invention relates to bicyclic heteroaryl cycloalkyldiamine derivatives, to processes for their production, to their use as SYK inhibitors and to pharmaceutical compositions comprising them. Formula (I) 

Bicyclic heteroaryl cycloalkyldiamine derivatives

The present invention relates to monocyclic heteroaryl cycloalkyldiamine derivatives of formula (I), to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them. 

Monocyclic heteroaryl cycloalkyldiamine derivatives

Growing community of inventors

Niffer, France

Alexander Baxter Smith